Literature DB >> 9484356

Do antiarthritic drugs decrease the risk for cognitive decline? An analysis based on data from the MRC treatment trial of hypertension in older adults.

M Prince1, S Rabe-Hesketh, P Brennan.   

Abstract

We ascertained nonsteroidal anti-inflammatory drug (NSAID) use in 2,651 participants in the UK MRC treatment trial of hypertension in older adults and measured change in cognitive function over the subsequent 54 months. There was a significant, although modest, association between change in the Paired Associate Learning Test score over time and NSAID use, which was modified by age. NSAID users showed less decline, with younger subjects seeming to benefit more than older. We found no relationship between NSAID use and time taken to complete the Trail Making Test and also no relationship between anti-indigestion drug use and either cognitive outcome. These analyses highlight the need for larger studies with prospective classification of NSAID use and adequate control of confounding, including exposure to other medications. A randomized controlled trial of NSAIDs, in those known to be at risk of cognitive decline or dementia, may be indicated in the future.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484356     DOI: 10.1212/wnl.50.2.374

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.

Authors:  Barbara K Martin; Christine Szekely; Jason Brandt; Steven Piantadosi; John C S Breitner; Suzanne Craft; Denis Evans; Robert Green; Michael Mullan
Journal:  Arch Neurol       Date:  2008-05-12

2.  Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study.

Authors: 
Journal:  Alzheimers Dement       Date:  2014-07-09       Impact factor: 21.566

Review 3.  Diagnosis of dementia and treatment of Alzheimer's disease. Pharmacologic management of disease progression and cognitive impairment.

Authors:  R van Reekum; M Simard; K Farcnik
Journal:  Can Fam Physician       Date:  1999-04       Impact factor: 3.275

Review 4.  The prediction and prevention of Alzheimer's disease--towards a research agenda.

Authors:  R van Reekum; M Simard; T Cohen
Journal:  J Psychiatry Neurosci       Date:  1999-11       Impact factor: 6.186

5.  Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder?

Authors:  L V Kessing; P K Andersen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-12       Impact factor: 10.154

Review 6.  Dementia and its implications for public health.

Authors:  Daniel P Chapman; Sheree Marshall Williams; Tara W Strine; Robert F Anda; Margaret J Moore
Journal:  Prev Chronic Dis       Date:  2006-03-15       Impact factor: 2.830

7.  Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial.

Authors:  Jackie F Price; Marlene C Stewart; Ian J Deary; Gordon D Murray; Peter Sandercock; Isabella Butcher; F Gerald R Fowkes
Journal:  BMJ       Date:  2008-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.